Tocqueville Asset Management L.P. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,315 shares of the biopharmaceutical company’s stock, valued at approximately $2,067,000.
Several other institutional investors also recently added to or reduced their stakes in REGN. DCF Advisers LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $5,768,000. Mmbg Investment Advisors CO. bought a new position in Regeneron Pharmaceuticals during the second quarter worth $231,000. West Family Investments Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter worth $634,000. Denali Advisors LLC raised its stake in Regeneron Pharmaceuticals by 100.0% during the 2nd quarter. Denali Advisors LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $624,000 after purchasing an additional 500 shares during the last quarter. Finally, NewEdge Wealth LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $603,000. 83.31% of the stock is owned by institutional investors.
Regeneron Pharmaceuticals Stock Down 1.7%
Shares of REGN stock opened at $826.64 on Friday. The stock has a market cap of $85.11 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 1.43 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $844.92. The stock has a fifty day moving average price of $692.65 and a 200 day moving average price of $715.90. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.
Analyst Ratings Changes
Several analysts have issued reports on REGN shares. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research report on Tuesday, July 7th. Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Truist Financial increased their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, HSBC decreased their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $801.70.
Get Our Latest Research Report on Regeneron Pharmaceuticals
Insider Activity
In related news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at $482,400. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,400 shares of company stock worth $1,090,030. Corporate insiders own 6.97% of the company’s stock.
Key Headlines Impacting Regeneron Pharmaceuticals
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes abnormal bone formation. Approval was supported by Phase 3 OPTIMA data showing a 90% or greater reduction in new heterotopic-ossification lesions at 56 weeks, along with fewer clinician-assessed flare-ups. Pasatru is described as the first and only FDA-approved treatment demonstrating these benefits, adding a specialized rare-disease product to Regeneron’s commercial portfolio. Reuters FDA approval article
- Positive Sentiment: The approval creates a potential new revenue stream and strengthens Regeneron’s focus on high-complexity immunology and rare diseases. However, FOP’s very small patient population limits the drug’s absolute market opportunity, while competition from Ipsen could affect adoption and sales. BioPharma Dive Pasatru article
- Neutral Sentiment: Regeneron also reported an update to its Phase 2 study of olatorepatide, signaling continued efforts to enter the obesity-treatment market. The trial remains mid-stage, so any commercial benefit is still several steps away and dependent on future efficacy and safety results. TipRanks olatorepatide article
- Neutral Sentiment: Leerink Partners raised its price target to $824, indicating limited near-term upside relative to the trading level and suggesting the FDA approval may already be substantially reflected in the valuation. Leerink Partners price-target article
- Negative Sentiment: Multiple law firms publicized a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to disclosures surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol amendment and concerns that previously positive messaging did not adequately reflect statistical and trial risks. The notices are largely duplicative, but they reinforce legal, reputational and pipeline uncertainty for REGN. Regeneron securities class-action notice
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
